| Bioactivity | Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment. | ||||||
| Invitro | Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM[1]. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1[3]. | ||||||
| Name | Semaglutide | ||||||
| CAS | 910463-68-2 | ||||||
| Formula | C187H291N45O59 | ||||||
| Molar Mass | 4113.64 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Semaglutide
CAS: 910463-68-2 F: C187H291N45O59 W: 4113.64
Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the po
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.